Hepatitis delta is rare, brutal, and until late May had no approved therapy in the United States. Now it has one, Gilead Sciences’ Hepcludex, and as of Sunday it has a serious rival in development. Vir Biotechnology’s Phase 3 ECLIPSE 1 trial met its primary endpoint, and the question for investors today is whether that result is worth betting on against an entrenched first mover.
What the Data Actually Show
The ECLIPSE 1 trial showed that 44% of participants achieved undetectable hepatitis delta virus levels after 48 weeks, significantly outperforming the control group. The comparison is sharp: the delayed-treatment response rate was zero, with a p-value below 0.0001. But the headline figure requires a footnote. After 48 weeks, 79% of treated patients had virus levels too low for tests to detect; a smaller group, 44%, also had normal levels of ALT, the liver enzyme used to assess liver injury. The 44% figure, which met the primary endpoint, reflects that stricter combined criterion.
ECLIPSE 1 randomized 124 adults, assigning 83 to monthly elebsiran and tobevibart and 41 to delayed treatment. Vir reported one severe treatment-related drop in neutrophils that resolved within 15 days. For a disease where patients can rapidly progress to cirrhosis, liver failure, and liver-related death, a clean tolerability profile matters as much as the efficacy numbers.
The Hepcludex Comparison
Gilead received accelerated FDA approval for Hepcludex on May 22, 2026, making it the first approved U.S. therapy for the disease. In the pivotal study used for approval, 48% of patients who received Hepcludex met the combined response endpoint at Week 48, compared with 2% of those in the delayed-treatment group. On that metric, Vir’s 44% combined response is competitive, though direct cross-trial comparisons carry obvious caveats about patient populations and endpoint definitions.
The more important differentiator may be the regimen. Vir’s combination is designed to address chronic hepatitis delta at multiple points, delivering monthly dosing in a format with potential for at-home or in-office use. Hepcludex is given as a once-daily subcutaneous injection. If Vir earns approval, convenience alone gives prescribers a reason to look.
What’s Coming Next
Phase 2 SOLSTICE data disclosed by Vir showed undetectable viral loads in patients completing 96 weeks of treatment, and an exploratory analysis showed all ten patients who stopped therapy after maintaining undetectable virus levels sustained viral suppression during follow-up periods of 12 to 48 weeks, suggesting the possibility of a functional cure in a subset. That is early-stage and small-sample, but it is the kind of signal that reshapes a market.
Vir has said it plans to seek FDA approval in mid-2027. The company hosts its investor call this morning at 8:30am ET with full data presented at AASLD’s Liver Meeting in Denver.
The Competitive Landscape
Vir is not the only challenger. Mirum Pharmaceuticals’ brelovitug is being evaluated in the global Phase 3 AZURE clinical program, and on September 28, 2026 Mirum announced that the Phase 3 portion of AZURE-1 achieved its primary combined endpoint of virologic response and ALT normalization at Week 24 in both dose arms. Brelovitug carries FDA Breakthrough Therapy Designation for the treatment of chronic HDV. Both Vir and Mirum are aiming for mid-2027 submissions, which means the market could see two new approvals within months of each other.
Bull and Bear
The bull case is straightforward: Vir has Phase 3 data, a clean safety record, a monthly dosing advantage over the only current approved option, and Phase 2 signals pointing toward finite treatment. In the wake of the update, some analysts have raised their price targets on the stock.
The bear case centers on execution. The company plans to file for FDA approval by mid-2027, which requires supportive data beyond ECLIPSE 1. Any stumble resets the clock. Mirum arrives with Breakthrough Therapy status and commercial infrastructure already built around rare liver disease. And Gilead, with Hepcludex already on the market and physician relationships established, has the incumbent advantage.
Bottom Line
ECLIPSE 1 is real, the tolerability data look clean, and the monthly regimen is a genuine differentiator. Data aggregators tracking Wall Street estimates put the consensus analyst rating heading into today at Moderate Buy with an average price target around $22. Two pivotal readouts stand between Vir and an FDA filing. Watch the next ECLIPSE trial results as they arrive. If they hold, the investment case gets substantially harder to argue against.
